Core Viewpoint - Enliven Therapeutics, Inc. has successfully completed a public offering of approximately 9.92 million shares of common stock, raising about $230 million in gross proceeds before expenses [1]. Group 1: Offering Details - The public offering included the full exercise of underwriters' option to purchase an additional 1,526,250 shares at a price of $19.66 per share [1]. - In addition to common stock, pre-funded warrants to purchase 1,780,263 shares were offered at a price of $19.659 per warrant, reflecting the common stock price minus a nominal exercise price [1]. - The offering was managed by Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho, with LifeSci Capital serving as the lead manager [2]. Group 2: Regulatory Information - The offering was conducted under a Registration Statement on Form S-3, which was previously filed and declared effective by the SEC [3]. - A final prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are accessible through the SEC's website [3]. Group 3: Company Overview - Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics aimed at improving patient survival and overall well-being [5]. - The company employs a precision oncology approach to address unmet medical needs, leveraging insights into validated biological targets and innovative chemistry [5].

ELVN-001 Positioning and Market Opportunity - The BCR::ABL1 TKIs market has historically generated approximately $6 billion in combined annual sales, even with generic options available[10] - There is a potential $9 billion opportunity in the U S alone for differentiated TKIs, which is validated by the successful launch of Scemblix[10] - The U S branded CML market has the potential to reach approximately $9 billion based on historical sales, adjusted for current prevalence and pricing[28] CML Landscape and Treatment - Prior to imatinib, the annual CML survival rate was less than 20%[14] - The 10-year survival rate for CML improved from less than 20% to over 80%[14] - Approximately 30% of second-line patients switch therapy within the first year of treatment[22] - Approximately 25% of first-line patients switch therapy within the first year[22] - In Q1 2025, Novartis reported Scemblix NBRx of 40% in 2L and 10% in 1L in the U S, highlighting the need for improved treatment options across all lines of therapy[32] ELVN-001 Clinical Data and Development - In the Phase 1 trial, the overall MMR (BCR::ABL1 ≤ 0 1%) by 24 weeks was 47% (25/53)[68] - 80% of patients in the ELVN-001 Phase 1 trial remained on the study, with a median duration of exposure of 29 weeks[58, 59] - The company expects to initiate the first ELVN-001 head-to-head pivotal trial in 2026[10]

Enliven Therapeutics (ELVN) Update Summary Company Overview - **Company**: Enliven Therapeutics - **Program**: ELVN001, targeting chronic myeloid leukemia (CML) Industry Context - **Market Size**: CML represents a large market with significant unmet needs, with a potential $9 billion opportunity in the U.S. alone [doc id='45'] - **Current Treatment Landscape**: The treatment of CML has evolved, focusing on quality of life and tolerability, with approximately 30% of patients switching therapies within a year due to intolerance or lack of response [doc id='7'][doc id='8'] Core Points and Arguments 1. **ELVN001's Potential**: ELVN001 is designed to address unmet needs in CML and has shown a potentially best-in-class profile in heavily pretreated patients [doc id='5'][doc id='6'] 2. **Regulatory Pathway**: Historical phase one data in CML has accurately predicted success in pivotal trials, allowing for smaller and faster studies [doc id='5'] 3. **Patient Population**: The ongoing phase one trial has enrolled a heavily pretreated population, with 72% of patients having discontinued their last TKI due to lack of efficacy [doc id='20] 4. **Efficacy Results**: - 47% of patients achieved major molecular response (MMR) by 24 weeks, with 32% achieving MMR and 100% maintaining MMR [doc id='24'] - 77% of patients achieved MR2 by 24 weeks, indicating robust efficacy despite the heavily pretreated population [doc id='25] 5. **Comparison with Osiminib**: ELVN001's efficacy appears favorable compared to osiminib, with a higher MMR rate in a more heavily pretreated population [doc id='27][doc id='36'] 6. **Safety Profile**: ELVN001 has shown a favorable safety profile, with low rates of dose reductions and discontinuations due to adverse events [doc id='31][doc id='34] 7. **Dosing Convenience**: ELVN001 supports once-daily dosing with or without food, addressing key challenges with current TKIs [doc id='34][doc id='77] Additional Important Insights - **Market Dynamics**: The CML market supports multiple blockbuster drugs despite the presence of generics, with TKI switching dynamics indicating a need for better treatment options [doc id='12] - **Emerging Competition**: Osiminib has rapidly penetrated earlier lines of therapy, but high discontinuation rates (50% within two years) indicate a significant opportunity for ELVN001 [doc id='11] - **Next Steps**: Enliven Therapeutics plans to initiate a pivotal trial for ELVN001 in 2026, with a focus on both late-line and frontline settings [doc id='16][doc id='44] Conclusion - Enliven Therapeutics is optimistic about the potential of ELVN001 to become a preferred treatment option for CML, with a clear regulatory path and promising early data supporting its efficacy and safety profile [doc id='46]

Company Overview - Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics aimed at improving survival and overall well-being through a precision oncology approach [5]. Offering Details - Enliven has priced its public offering of 8,394,737 shares of common stock at $19.66 per share, with an option for investors to purchase pre-funded warrants for an additional 1,780,263 shares at $19.659 each [1]. - The gross proceeds from the offering are expected to be approximately $200 million before deducting underwriting discounts and commissions [1]. - The offering is expected to close on or about June 16, 2025, subject to customary closing conditions [1]. - Enliven has granted underwriters a 30-day option to purchase up to an additional 1,526,250 shares at the public offering price [1]. Underwriters - Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho are acting as joint book-running managers for the offering, with LifeSci Capital serving as the lead manager [2]. Regulatory Compliance - The offering is being made pursuant to a Registration Statement on Form S-3, which has been filed with and declared effective by the SEC [3]. - A final prospectus supplement and accompanying prospectus will be filed with the SEC [3]. Strategic Focus - Enliven aims to address unmet medical needs with a focus on developing potentially first-in-class or best-in-class therapies through insights in clinically validated biological targets and differentiated chemistry [5].

Core Viewpoint - Enliven Therapeutics, Inc. has initiated an underwritten public offering of $200 million in common stock and pre-funded warrants, with an additional option for underwriters to purchase up to $30 million more [1][2]. Company Overview - Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics aimed at improving survival and overall well-being through precision oncology [5]. - The company is based in Boulder, Colorado, and aims to address unmet medical needs with potentially first-in-class or best-in-class therapies [5]. Offering Details - The offering is being conducted under a Registration Statement on Form S-3, which has been declared effective by the SEC [3]. - The offering includes common stock and pre-funded warrants, with the final terms subject to market conditions [1][3]. - Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho are acting as joint book-running managers for the offering, with LifeSci Capital as the lead manager [2].

Core Insights - Enliven Therapeutics announced positive data from the Phase 1 ENABLE clinical trial for ELVN-001, a treatment for chronic myeloid leukemia (CML), showing a cumulative major molecular response (MMR) rate of 47% and an achieved MMR rate of 32% by 24 weeks [1][11] - The trial demonstrated a favorable safety and tolerability profile, with only 3.4% of patients experiencing dose reductions due to treatment-emergent adverse events (TEAEs) and 4.6% discontinuing treatment due to TEAEs [11] Company Overview - Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics aimed at improving the quality of life and survival for patients [13] - The company is based in Boulder, Colorado, and aims to address unmet needs in precision oncology [13] Clinical Trial Details - The ENABLE trial is a Phase 1 study evaluating ELVN-001 in previously treated CML patients, with a focus on safety, tolerability, and determining the recommended dose for further evaluation [9] - As of April 28, 2025, 90 patients were enrolled, with a median treatment duration of approximately 29 weeks [5] Efficacy Data - Among 53 evaluable patients, 25 (47%) achieved MMR by 24 weeks, with 13 of 41 (32%) achieving and 12 of 12 (100%) maintaining MMR [5][11] - The trial included heavily pretreated patients, with 67% having received three or more prior TKIs [5] Safety Profile - ELVN-001 was well tolerated across all evaluated doses, with low levels of dose reductions and discontinuations [11] - The maximum tolerated dose was not reached, and the pharmacokinetic profile supports once-daily dosing [11][12] Future Outlook - Enliven plans to initiate a head-to-head Phase 3 pivotal trial for ELVN-001 in 2026, leveraging insights from historical Phase 1 data to guide regulatory pathways [7][9]

Summary of Enliven Therapeutics (ELVN) 2025 Conference Call Company Overview - Enliven Therapeutics is a clinical stage precision oncology company based in Boulder, Colorado, focusing on kinase drug discovery and development, particularly for chronic myeloid leukemia (CML) [4][5] Key Points Discussed Product Pipeline and Clinical Trials - The lead asset, ELVN001, is a highly selective ATP competitive inhibitor of BCR ABL for treating CML [4] - A Phase I study is ongoing for patients not expected to respond to approved BCR ABL TKI therapies, with data updates expected at the EHA conference on June 13 [7][8] - Recent data showed a cumulative major molecular response (MMR) rate of 44% and a response achieved rate of 26% in heavily pretreated patients [8][9] - The number of efficacy evaluable patients increased from 36 to approximately 90, indicating a more robust dataset for analysis [11][12] Efficacy Metrics - The response achieved rate correlates well with historical pivotal studies, suggesting reliability in the efficacy metrics [8][9] - The company aims to compare ELVN001 against Osiminib, a second-generation ATP competitive inhibitor, in pivotal studies [16][18] - The data presented will include various molecular markers and response rates, including achievement of less than 1% BCR ABL, which is critical for assessing efficacy [23][24] Safety and Tolerability - Safety data indicates that the majority of adverse events (AEs) are consistent with the class, with no new concerning toxicities reported [45][49] - The company has a solid safety profile, with a focus on tolerability as a key driver for drug use in CML patients [51] Future Plans and Market Potential - The company is preparing for a pivotal study, with dose selection expected to be between 60 mg and 120 mg, likely favoring 80 mg based on target coverage [54][56] - There is a significant commercial opportunity in the second-line plus setting, potentially accessing a patient population 2.5 times larger than the third-line plus setting [68][69] - The company is excited about the potential for a more attractive comparator arm in future studies, which could enhance market positioning [60][68] Financial Position - Enliven Therapeutics has a strong cash position in the upper $200 million range, providing a runway into late 2027 [76] Additional Insights - The company is winding down two programs to prioritize resources for the lead asset, with potential updates on new clinical programs expected next year [73][74] - The upcoming data presentation at EHA is anticipated to provide further insights into the efficacy and safety of ELVN001, which could bolster investor confidence [76][78]

Summary of Enlivant Therapeutics Conference Call Company Overview - Enlivant Therapeutics is a clinical-stage precision oncology company focused on small molecule kinase drug discovery, with all assets developed in-house [2][3] - The lead program is ELVN001, a selective ATP competitive BCR ABL inhibitor for chronic myeloid leukemia (CML) [3] Industry Context - CML has a large precision oncology market, benefiting from multiple approved TKI inhibitors over the past 25 years, leading to improved patient survival rates [4] - Evolving treatment goals in CML focus on quality of life, convenience, and deeper molecular responses [4] Key Data and Efficacy Measures - The company is preparing to present updated data for ELVN001 at the upcoming EHA conference, with a focus on major molecular response (MMR) rates [6][10] - Previous data showed a cumulative major molecular response rate of 44% by six months in heavily pretreated patients [7] - The response achieved rate was 23% in a subset of patients, which compares favorably to the best-in-class agent, osiminib, which had a 24% response achieved rate [9][10] - The number of evaluable patients for efficacy is expected to increase from 36 to approximately 50 by the EHA presentation [11][12] Safety and Tolerability - Safety and tolerability are critical for chronic therapies, with less than 5% dose reductions reported, which is favorable compared to precedent studies [15] - No new toxicities have been observed, and the drug has shown high specificity for BCR ABL, with fewer gastrointestinal side effects compared to first and second-generation TKIs [16][17] Future Trials and Market Positioning - Enlivant plans to initiate pivotal trials next year, considering both a head-to-head study against existing therapies and a more aggressive second-line study [26][29] - The company aims to position ELVN001 primarily for patients who have previously been treated with Semblix, with potential for use in earlier lines of therapy [41][42] Market Insights - The launch of Semblix has been financially successful, with projected sales of $689 million in 2024 and potential to exceed $5 billion due to its broad approval [36][38] - Enlivant's strategy is to leverage the differentiated mechanism of action of ELVN001 to capture market share in a competitive landscape [38][39] Strategic Decisions - The company has decided to seek strategic alternatives for its second program, o o two, due to cost considerations and competitive landscape challenges [45][46] - Focus will remain on advancing ELVN001, which has garnered significant investor interest and confidence [47] Conclusion - Enlivant Therapeutics is poised to present promising data for ELVN001, with a strong focus on efficacy, safety, and market positioning in the CML treatment landscape, while strategically managing its resources and future trial designs [48][50]

Company Overview - Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics aimed at improving both longevity and quality of life [3] - The company employs a precision oncology approach to address existing and emerging unmet medical needs, enhancing survival and overall well-being [3] - Enliven's discovery process integrates insights from clinically validated biological targets with differentiated chemistry to create potentially first-in-class or best-in-class therapies [3] Upcoming Events - Enliven will present at the TD Cowen's 6th Annual Oncology Innovation Summit on May 27, 2025, at 1:00 p.m. ET in a fireside chat format [1] - The company will also participate in the Jefferies Global Healthcare Conference on June 4, 2025, at 4:20 p.m. ET, again in a fireside chat format [1] - Additionally, Enliven is scheduled to present at the Goldman Sachs Annual Global Healthcare Conference on June 10, 2025, at 4:00 p.m. ET [2] - All fireside chats will be webcast live and archived for 90 days on the company's investor relations website [2]

Financial Performance - The company reported a net loss of $28.5 million for the three months ended March 31, 2025, compared to a net loss of $22.7 million for the same period in 2024, reflecting an increase in losses of approximately 25.5%[132] - Total operating expenses for the three months ended March 31, 2025, were $31.7 million, up from $26.0 million in the same period of 2024, representing an increase of about 22.5%[132] - General and administrative expenses rose to $6.8 million for the three months ended March 31, 2025, compared to $6.0 million in the same period of 2024, an increase of 13.3%[135] - Net cash used in operating activities was $24.1 million for the three months ended March 31, 2025, compared to $23.4 million for the same period in 2024, reflecting a 3.0% increase[148][149] - The accumulated deficit as of March 31, 2025, was $272.0 million, indicating significant losses since inception[116] - The company has not generated any revenue to date and does not expect to do so in the foreseeable future[122] Research and Development - Research and development expenses increased to $24.9 million for the three months ended March 31, 2025, compared to $20.0 million for the same period in 2024, marking a rise of approximately 24.5%[132] - The company plans to explore strategic alternatives for the ELVN-002 program and does not intend to pursue its development beyond 2025[110] - The company is advancing the ELVN-001 program, which is currently in Phase 1 safety and efficacy trials, with a pivotal trial expected in mid-2025[111] Capital and Funding - The company has raised a total of $140.5 million from private placements and $164.5 million from common stock sales, with an additional $90.0 million raised in a recent private placement[114][115] - The company expects to require substantial additional capital to fund operations and product development, as it has not generated any revenue from product sales[140][141] - The company has a shelf registration statement allowing for equity and debt offerings up to $400.0 million, with $200.0 million available for use under this statement as of March 31, 2025[138] Cash and Liquidity - The company had cash, cash equivalents, and marketable securities of $289.6 million as of March 31, 2025, which is expected to fund operations for at least the next 12 months[115] - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $289.6 million[139] - The company's cash, cash equivalents, and marketable securities primarily consist of U.S. Treasury securities and U.S. Treasury-backed money market funds[159] Lease and Obligations - The company entered into a non-cancellable operating lease for approximately 20,011 rentable square feet of office and laboratory space, with total lease obligations of $714,000 due in 2025[154] Risk Management - As of March 31, 2025, the company had no debt outstanding, eliminating exposure to interest rate risk related to debt[160] - A hypothetical 100 basis point increase or decrease in interest rates would not have had a material impact on the company's financial results due to the short-term maturities of investments[159] - The company does not currently engage in hedging activities to mitigate foreign currency transaction risks but may consider it in the future[161] - A hypothetical 100 basis point increase or decrease in foreign exchange rates would not have had a material impact on the company's financial condition or results of operations[161] Accounting Policies - There have been no material changes to the company's critical accounting policies and estimates since the last annual report[157] - The company evaluates its estimates and assumptions on a periodic basis, which may differ from actual results[157] - Recently issued accounting pronouncements that may impact the company's financial condition are disclosed in the quarterly report[158]